Pembrolizumab, Enfortumab Vedotin, Ivonescimab Dose 1, Ivonescimab Dose 2, Ivonescimab Rp3d
Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (Uc)
Phase II/III
Recruiting
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Aug 31, 2026
―
Cetuximab, Daraxonrasib, Ivonescimab, Elironrasib, Zoldonrasib, Carboplatin/Cisplatin + Pemetrexed
Advanced Solid Tumors, Non-Small Cell Lung Cancer (Nsclc), Nsclc, Metastatic Solid Tumors, Colorectal Cancer (Crc), Crc
Phase I/II
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Feb 02, 2026
Oxaliplatin, Irinotecan, Capecitabine, Leucovorin, 5-Fluorouracil, Ak112, Ak117
Metastatic Colorectal Cancer
Phase II
Active Not Recruiting
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
May 16, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Summit Therapeutics (SMMT) have in its pipeline
SMMT is currently developing the following drugs: Pembrolizumab, Enfortumab Vedotin, Ivonescimab Dose 1, Ivonescimab Dose 2, Ivonescimab Rp3d, Carboplatin, Ak138d1, Ivonescimab, Cetuximab, Daraxonrasib, Ivonescimab, Elironrasib, Zoldonrasib, Carboplatin/Cisplatin + Pemetrexed. These drug candidates are in various stages of clinical development as the company works toward FDA approval.